Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2025-03-17 Regulatory Filings
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 17, 2025, by Protalix BioTherapeutics, Inc. It announces the issuance of a press release with financial results for the fiscal year ended December 31, 2024, and a business and clinical update. The document itself does not contain the full financial results or detailed financial statements but rather furnishes the press release as an exhibit. The length is 3778 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for such filings that do not fit other categories and are announcements or certifications rather than full reports.
2025-03-17 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on amendments to the company's bylaws, including changes to stockholder rights and procedural rules. It does not contain financial statements or detailed financial performance data. The document is not an annual or quarterly report, nor is it an earnings release or audit report. It is also not a proxy statement or voting results announcement. The primary purpose is to disclose a material corporate governance change, specifically amendments to the articles of incorporation or bylaws. According to the filing definitions, announcements of changes in company governance documents fall under Regulatory Filings (RNS) if they do not fit more specific categories. Since this is a Form 8-K reporting bylaw amendments and does not fit other categories, the appropriate classification is Regulatory Filings (RNS). The document length (5668 characters) and content confirm it is a full filing, not just a report publication announcement.
2024-12-31 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release and a letter to stockholders but does not contain detailed financial statements or comprehensive financial analysis. The document length is 3694 characters, which is relatively short and consistent with an announcement rather than a full report. The document explicitly states it is a Current Report on Form 8-K and includes a press release as an exhibit. There is no indication of detailed financial data or management discussion that would classify it as an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). The content fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes Form 8-K filings.
2024-12-23 English
10-Q
Interim / Quarterly Report Q3 2024
2024-11-14 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 14, 2024, reporting the issuance of a press release announcing financial results for the fiscal quarter ended September 30, 2024. The text explicitly states that the press release is furnished as an exhibit and that the Form 8-K is a current report, not the full quarterly report itself. The document length is 3791 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. The content corresponds to an initial announcement of quarterly financial results, which aligns with the definition of an Earnings Release (ER). Therefore, the appropriate classification is Earnings Release (ER).
2024-11-14 English
Director's Dealing 2024
Director's Dealing
2024-11-05 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.